Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826196 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
A Phase 1 study of Alopecia Areata (AA), sponsored by Aldena Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT06826196 is a Phase 1 study of Alopecia Areata (AA) that is actively recruiting participants, run by Aldena Therapeutics. The registered enrollment target is 24 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT06826196, a Phase 1 study of Alopecia Areata (AA), is actively recruiting participants, sponsored by Aldena Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks for a treatment period of 8 weeks.
Conditions Studied
Interventions
- DRUG ALD-102 Solution
- OTHER Placebo or Control
Study Locations (7)
Quebec
- Innovaderm - Montreal
- Centre de Recherche Saint-Louis - Québec
California
- Clinical Trial Research Institute - Thousand Oaks
Indiana
- Options Research Group - West Lafayette
Massachusetts
- The Brigham and Women's Hospital - Boston
Washington
- Dermatology Specialists of Spokane - Spokane
Ontario
- The Centre for Clinical Trials - Oakville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06826196
The ClinicalTrials.gov registry entry for NCT06826196 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldena Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata (AA) appearing as the primary indexed condition, and to 2 interventions - of which ALD-102 Solution is the first listed.
NCT06826196 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Quebec, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06826196 about?
NCT06826196 is a clinical study titled "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata". The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the ef...
What is the current status of trial NCT06826196?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-03-24. Estimated completion is 2026-12.
What conditions does trial NCT06826196 study?
This clinical trial studies the following conditions: Alopecia Areata (AA).
What interventions are being tested in trial NCT06826196?
The interventions under investigation include: ALD-102 Solution (DRUG), Placebo or Control (OTHER).
Who is sponsoring clinical trial NCT06826196?
This trial is sponsored by Aldena Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826196 being conducted?
This trial has 7 study locations across California, Indiana, Massachusetts, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata (AA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.